Covid-19 (Temas de Saúde Pública)
Covid: pesquisa mostra que a atualização das máscaras reduz o risco de infecção.
30 Jun, 2021 | 10:44hCovid: Masks upgrade cuts infection risk, research finds – BBC
Devo tomar a segunda dose da vacina da AstraZeneca? Sim; ela quase dobra sua proteção contra a variante Delta.
30 Jun, 2021 | 10:41hRelacionado: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – medRxiv
Projeções do IHME para COVID-19 foram atualizadas para mais de 200 localidades do mundo.
29 Jun, 2021 | 09:56hCOVID-19 Projections – Institute for Health Metrics and Evaluation
Vídeo: Insights from IHME’s latest COVID-19 model update
Comentário no Twitter
📣 NEW ✨ Our COVID-19 model has been updated for over 200 world locations 🌎 🌍 🌏 📊 (https://t.co/5biAggRz1T)
📺 Full video: https://t.co/wLGeAiiYhy
📄 PDFs with explanations of country-specific projections: https://t.co/9KQxWwhQqx pic.twitter.com/8sSEzyXEf8— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) June 27, 2021
Estudo randomizado fase 1/2 | CoronaVac é bem tolerada, segura e induz forte resposta humoral em crianças e adolescentes de 3 a 17 anos de idade.
29 Jun, 2021 | 09:54hComentário convidado: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases
Comentário no Twitter
NEW—A phase 1/2 clinical trial of #CoronaVac in 550 children and adolescents aged 3-17 years in China suggests two doses of the vaccine are safe and generate a strong antibody response. Read in @TheLancetInfDis: https://t.co/eXSagRu1Cs pic.twitter.com/fOKNLUjNwc
— The Lancet (@TheLancet) June 28, 2021
Vacinas de mRNA contra SARS-CoV-2 induzem respostas persistentes do centro germinativo humano, sugerindo uma imunidade de longa duração.
29 Jun, 2021 | 09:52hSARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature
Comentários: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical
Relacionado: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.
Comentário no Twitter (fio – clique para saber mais)
Just published @nature
A bonus factor after covid vaccination: germinal center factories for durable, antigen-specific, B cells and plasmoblasts induced by mRNA vaccination, as determined by lymph node aspirates from vaccinees https://t.co/5eR0gDSWHq@TheBcellArtist @WUSTLmed pic.twitter.com/C5xPSrh5Gw— Eric Topol (@EricTopol) June 28, 2021
[Preprint] Terceira dose da vacina da AstraZeneca propicia forte imunidade.
29 Jun, 2021 | 09:50hStudy: 3rd AstraZeneca shot gives strong immunity – Reuters
Estudo original (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet
O impacto permanente da pandemia de COVID nos estudos clínicos – “Pesquisadores médicos estão começando a tirar seus focos da COVID-19, mas a pandemia pode continuar afetando os estudos centrados em outras doenças.”
29 Jun, 2021 | 09:48hThe COVID pandemic’s lingering impact on clinical trials – Nature
Estudo randomizado de fase 2 | Imunogenicidade e reatogenicidade de dose de reforço da vacina da Pfizer-BioNTech em pacientes que receberam uma dose da vacina da AstraZeneca – “A vacina BNT162b2 (Pfizer), aplicada como segunda dose em indivíduos previamente vacinados com ChAdOx1-S (AstraZeneca), induziu uma resposta imune robusta, com perfil de reatogenicidade aceitável e controlável.”
28 Jun, 2021 | 10:48hComentários: Heterologous vaccine regimens against COVID-19 – The Lancet E
Comentário no Twitter (fio – clique para saber mais)
NEW #COVID19 research—Phase 2 trial by @borobia_am, @antoniojcarcas
et al. reports BNT162b2 given as a 2nd dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile. Read https://t.co/muL0XQxdjG. pic.twitter.com/BxPlXB8EF7— The Lancet (@TheLancet) June 26, 2021
OMS | Variante Delta é a “mais transmissível” identificada até o momento.
28 Jun, 2021 | 10:46hWHO: Delta variant is ‘most transmissible’ identified so far – Associated Press
Relacionado: Delta COVID variant fuels global surges, complicates reopenings – CIDRAP E Delta variant triggers dangerous new phase in the pandemic – Science E Delta coronavirus variant: scientists brace for impact – Nature E Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv E COVID-19: The rise and rise of Delta – Sciblogs E Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.
OMS insiste para que pessoas totalmente vacinadas continuem usando máscara enquanto a variante Delta se dissemina.
28 Jun, 2021 | 10:45hWHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads – CNBC
Comentário no Twitter (fio – clique para saber mais)
⚠️WEAR MASK EVEN IF VACCINATED—Top @WHO leader urges masks against #DeltaVariant even if 2-dose vaxxed. "Vaccine alone won't stop community transmission. People need to use masks consistently, be in ventilated spaces—even if you're vaccinated" #COVID19🧵https://t.co/qPZTmcy9iW pic.twitter.com/j5V6fbHdoi
— Eric Feigl-Ding (@DrEricDing) June 26, 2021